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Glutamate-mediated excitotoxicity has been implicated in the
pathogenesis of both acute and chronic neurodegeneration,
and defects in extracellular glutamate reuptake are consid-
ered important to the evolution of disorders, such as
amyotrophic lateral sclerosis (ALS), Alzheimer’s disease
(AD), and stroke (Rothstein et al. 1992, 1995; Masliah
et al.1996; Li et al. 1997; Mallolas et al. 2006). More
recently, loss of the excitatory amino acid transporters
(EAATs) has also been observed in lesions from patients with
infectious and inflammatory disorders of the CNS known to
have a neurodegenerative component (Werner et al. 2001;
Wang et al. 2004; Vercellino et al. 2007), thus broadening
the potential clinical relevance of impaired glutamate reup-
take. Not only have these recent data brought more focus
onto the general importance of neuroinflammation in the
pathogenesis of diseases, such as ALS and AD (Moisse and
Strong 2006; Wyss-Coray 2006), but they have also stim-
ulated further investigation into the specific roles played by
host immune responses in controlling extracellular glutamate
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Abstract
Astrocytes remove glutamate from the synaptic cleft via
specific transporters, and impaired glutamate reuptake may
promote excitotoxic neuronal injury. In a model of viral
encephalomyelitis caused by neuroadapted Sindbis virus
(NSV), mice develop acute paralysis and spinal motor neuron
degeneration inhibited by the AMPA receptor antagonist,
NBQX. To investigate disrupted glutamate homeostasis in the
spinal cord, expression of the main astroglial glutamate
transporter, GLT-1, was examined. GLT-1 levels declined in
the spinal cord during acute infection while GFAP expression
was preserved. There was simultaneous production of
inflammatory cytokines at this site, and susceptible animals
treated with drugs that blocked IL-1b release also limited
paralysis and prevented the loss of GLT-1 expression. Con-
versely, infection of resistant mice that develop mild paralysis
following NSV challenge showed higher baseline GLT-1 levels
as well as lower production of IL-1b and relatively preserved
GLT-1 expression in the spinal cord compared to susceptible
hosts. Finally, spinal cord GLT-1 expression was largely
maintained following infection of IL-1b-deficient animals.
Together, these data show that IL-1b inhibits astrocyte glu-
tamate transport in the spinal cord during viral encephalo-
myelitis. They provide one of the strongest in vivo links
between innate immune responses and the development of
excitotoxicity demonstrated to date.
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removal (Tilleux and Hermans 2007). Microglia, in partic-
ular, are implicated in the production of inflammatory
mediators that impair glutamate transport (Tilleux and
Hermans 2007), and drugs that inhibit microglial activation
have now been touted as a practical strategy to treat various
neurodegenerative disorders by dampening this effect
(McCarty 2006). Still, microglia may also serve a neuropro-
tective role, particularly in the setting of acute brain injury
(Simard and Rivest 2007). Thus, the in vivo relationship
between innate immune responses and neurodegeneration via
excitotoxicity pathways requires further study.
While EAATs have been identified on the plasma mem-
branes of both glia and neurons, astrocytes dominate the
extracellular glutamate reuptake process (Anderson and
Swanson 2000). In rodents, glutamate transporter-1 (GLT-1,
also known as EAAT2 in humans) is the main astrocytic
EAAT and is expressed widely throughout the CNS; it may
account for more than 90% of all CNS glutamate transport
(Rothstein et al. 1996; Tanaka et al. 1997). Expression and
function of GLT-1 by primary astrocytes can be suppressed in
vitro following exposure to the inflammatory cytokines,
interleukin (IL)-1b and tumor necrosis factor (TNF)-a (Ye
and Sontheimer 1996; Szymocha et al. 2000; Wang et al.
2003; Korn et al. 2005), yet inflammatory regulators of this
protein in vivo remain poorly defined. Nevertheless, GLT-1
expression is diminished within inflammatory CNS lesions of
both animals and humans (Ohgoh et al. 2002; Vercellino
et al. 2007), even if the mediators involved and the
functional consequences of this change remain unclear. An
improved understanding of the inflammatory regulators of
this protein directly within the CNS might eventually reveal
unique pharmacological strategies that could reduce excito-
toxicity in these disorders.
Alphaviruses are important causes of acute and often fatal
encephalomyelitis in humans. One of these pathogens,
neuroadapted Sindbis virus (NSV), causes acute encephalo-
myelitis in mice and closely reproduces many features of the
related human infections. Spread of NSV from neurons of the
brain to the spinal cord typically results in hind limb
paralysis in susceptible hosts (Jackson et al. 1987), although
a few inbred strains of mice are more resistant to this phase
of disease (Thach et al. 2000). Glutamate excitotoxicity has
recently been identified as an important mediator of neuronal
injury in the spinal cord during NSV infection (Darman et al.
2004; Nargi-Aizenman et al. 2004), and the fate of spinal
motor neurons determines the severity of paralysis among
infected mice. Host immune responses also contribute to the
development of this paralysis (Liang et al. 1999; Irani and
Prow 2007), leading us to investigate their connection to
excitotoxic pathways. Here, we report that the inflammatory
cytokine, IL-1b, is responsible for the loss of spinal cord
GLT-1 expression during infection. This results in excitotoxic
spinal motor neuron damage and the development of hind
limb paralysis. We propose that the link between CNS IL-1b
production and reduced GLT-1 expression could potentially
explain the occurrence of neuronal injury during other
neuroinflammatory disorders as well.
Materials and methods
Animal manipulations
All animal procedures had received prior approval from our
institutional animal care and use committee and were performed
under isoflurane anesthesia (Abbott Laboratories, Chicago, IL,
USA). Five week-old C57BL/6 and BALB/cBy mice were obtained
from The Jackson Laboratory (Bar Harbor, ME, USA). Animals
homozygous for IL-1b gene deficiency (IL-1b)/) mice) as well as
age- and strain-matched, but non-littermate, control animals (IL-
1b+/+ mice) were purchased directly from Taconic (Hudson, NY,
USA). To induce encephalomyelitis, 1000 plaque-forming units of
NSV suspended in 20 lL of phosphate-buffered saline (PBS) were
inoculated directly into the right cerebral hemisphere of each animal.
Mice were monitored daily for signs of disease and for survival in
accordance with approved animal protocols. Twenty animals per
group were used for all experiments unless otherwise noted. For
those experiments where spinal cord tissue samples were not being
collected for ex vivo analysis, each live animal was scored daily by a
blinded examiner into one of the following categories: (0) normal,
(1) mild paralysis (some weakness of one or both hind limbs), (2)
moderate paralysis (weakness of one hind limb, paralysis of the
other hind limb), or (3) severe paralysis (complete paralysis of both
hind limbs). Some animals received intraperitoneal treatments with
the following agents (obtained from Sigma–Aldrich, St Louis, MO,
USA) according to the following schedules: 1,2,3,4-tetrahydro-6-
nitro-2,3-dioxo-benzo(f)quinoxaline (NBQX, 30 mg/kg twice dai-
ly), MK-801 (1 mg/kg/day), naloxone hydrochloride (50 mg/kg/
day), minocycline (25 mg/kg twice daily), or a saline vehicle control
starting on the day after viral challenge.
Immunoblotting of tissue extracts
Animals designated for immunoblotting or tissue cytokine assays
were perfused with chilled PBS via a transcardial approach. To
prepare tissue samples for immunoblots, lumbar spinal cords were
dissected and sonicated in lysis buffer (10 mM Tris, 1% sodium
sodium dodecyl sulfate (SDS), 1 mM sodium orthovanadate, pH
7.6) after the addition of a protease inhibitor cocktail (Sigma–
Aldrich). Total protein concentrations were determined using a
commercial protein assay kit (Bio-Rad, Hercules, CA, USA). A total
of 5 lg of each sample was separated on 12% SDS-polyacrylamide
gels (Bioexpress, Kaysville, UT, USA). Separated proteins were
then transferred to Hybond-C extra nitrocellulose membranes
(Amersham Biosciences, Piscataway, NJ, USA) using an electro-
phoretic transfer system (Bio-Rad) in 20% methanol transfer buffer.
Membranes were blocked for 1 h in 5% non-fat skim milk diluted in
PBS containing 0.05% Tween-20, and incubated overnight in
primary antibody diluted in 1% non-fat skim milk in PBS. Primary
antibodies included anti-GLT-1 (Sigma–Aldrich, 1 : 200), anti-glial
fibrillary acidic protein (GFAP, Chemicon, Temecula, CA, USA,
1 : 1000), and anti-actin (Chemicon, 1 : 10 000). After washing,
membranes were incubated for 1 h at 25C with horseradish
peroxidase-conjugated secondary antibodies (Amersham, 1 : 5000),
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washed, developed with Supersignal West Pico chemiluminescent
substrate (Pierce, Rockford, IL, USA), and visualized using a Fuji
Luminsecent Image Analyzer (Fuji Photo Film Co., Ltd., Tokyo,
Japan). Each GLT-1 and GFAP blot was stripped and reprobed
for actin expression. The intensity of each band was determined
using ImageJ software (National Institutes of Health, Bethesda,
MD, USA), and GLT-1 or GFAP levels were normalized to actin
expression in each lane. In most cases, protein expression levels
in infected tissue samples were then normalized to levels present
in uninfected controls (set at 100%). Triplicate samples at each
time point were analysed, and the mean ± SEM of relative
expression levels or percent of control levels in uninfected tissue
are shown.
Tissue cytokine assays
IL-1b and TNF-a levels in spinal cord lysates made from tissues
derived from PBS-perfused animals were determined using ELISA
kits according to the manufacturer’s instructions (Biosource,
Camarillo, CA, USA). Each lysate was made in PBS and
standardized such that 50 lg of total spinal cord protein was
applied to each ELISA plate. Cytokine concentrations in each test
sample were calculated based on direct comparison to known
concentrations of a standard provided with each assay kit. Triplicate
samples at each time point and under each experimental condition
were analysed; the mean ± SEM of concentrations per lg of total
spinal cord protein are shown.
Histology
Animals designated for histological analyses were sequentially
perfused with chilled PBS and 4% paraformaldehyde in PBS via
a transcardial approach. Tissues were then post-fixed in 4%
paraformaldehyde overnight at 4C, after which they were
embedded in paraffin for sectioning. All spinal cord sections were
taken from the same level of the lumbar spinal cord to ensure
uniform comparisons between animals. To assess the fate of spinal
motor neurons, serial sections were prepared and every 20th
section was collected onto glass slides for staining with hematox-
ylin and eosin. Motor neurons were defined as cells present in the
spinal gray matter, ventral to the central canal, and having a cell
body > 25 lm in diameter. A blinded examiner counted these cells
under 20· magnification. Data are presented as the mean ± SEM
of the total number of motor neurons per section; 10 sections from
each animal were counted, and 3–5 animals were analyzed per
experimental group.
Immunohistochemistry
For immunoperoxidase staining, spinal cord sections were depa-
raffinized, rehydrated, treated with 1% hydrogen peroxide in ice-
cold methanol for 30 min to block endogenous peroxidase, and
rinsed in PBS. Sections were blocked with 1% normal serum
matching the animal in which the secondary antibody was raised for
1 h at 25C. Primary antibody was applied to each section, diluted
in PBS containing 0.5% non-fat skim milk plus 1% normal serum
overnight at 4C. The following primary antibodies were utilized:
anti-GFAP (Chemicon, 1 : 200) or anti-GLT-1 (Sigma–Aldrich,
1 : 80). Secondary antibodies were conjugated to biotin and used at
1 : 200 (Vector Laboratories, Burlingame, CA, USA). Following
several more washes to remove all unbound secondary antibody,
sections were sequentially incubated with avidin-DH-biotin
complex solution (Vector Laboratories) in PBS, and then treated
with 0.5 mg/mL diaminobenzidine (Polysciences, Warrington, PA,
USA) containing 0.01% hydrogen peroxide. All sections were
(a)
(b)
Fig. 1 Blockade of the AMPA subtype of glutamate receptors limits
paralysis and spinal motor neuron degeneration in mice with NSV
encephalomyelitis. (a) Parallel groups of animals were challenged with
NSV and treated with the AMPA receptor antagonist, NBQX (30 mg/kg
twice daily), or a vehicle control. A blinded examiner scored paralysis
on a daily basis among surviving animals using a standardized scale;
the proportion of mice with either normal findings or mild paralysis is
shown. Drug treatment also reduced mortality in these animals (45%
in the NBQX group, 100% in the control group, p = 0.0004), demon-
strating that the disease severity differences shown are not due to a
subtle shift between mild and moderate paralysis scores. The signifi-
cance of paralysis and survival differences was determined by Kap-
lan–Meier analysis. (b) This same NBQX treatment regimen enhanced
the survival of lumbar motor neurons in NSV-infected animals.
Mean ± SEM of motor neuron counts in lumbar spinal cord tissue
sections are shown (*p < 0.05 favoring drug-treated animals com-
pared to vehicle-treated controls at each time point was determined
via the Kruskal–Wallis test).
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counterstained with hematoxylin (Fisher Scientific, Fair Lawn, NJ,
USA), dehydrated in graded alcohol washes, mounted with glass
coverslips in Permount (Fisher), and directly visualized using light
microscopy for photography using Spot advanced software, version
4.0.1 (Diagnostic Instrument Inc., Sterling Heights, MI, USA).
Statistical analysis
GraphPad Prism, version 4.02, was used for all statistical analyses
(GraphPad Software Inc, San Diego, CA, USA). The significance of
paralysis or survival differences between experimental groups was
determined by Kaplan–Meier analysis. The Kruskal–Wallis test was
performed to analyze differences between groups at individual time
points, and Friedman’s non-parametric repeated measures compar-
ison was used to analyze differences across time within an
individual group. Because of the non-parametric nature of the data,
non-parametric equivalent tests of ANOVA and repeated measures
ANOVA were used to increase the robustness of the results.
Significance in all experiments was assessed at the 0.05 level.
Results
AMPA receptor blockade inhibits paralysis and promotes
motor neuron survival
Glutamate excitotoxicity has recently been identified as an
important mediator of NSV-induced neuronal injury both
in vitro and in vivo (Nargi-Aizenman and Griffin 2001;
Darman et al. 2004; Nargi-Aizenman et al. 2004). To
determine the role of specific glutamate receptor subtypes
in the development of paralysis and motor neuron degen-
eration following NSV infection in vivo, animals were
treated with different glutamate receptor antagonists and
clinical and histological parameters were followed over
time. The prototype NMDA receptor blocking drug, MK-
801, had no effect on either the course of disease or on the
degeneration of spinal motor neurons at the maximum
tolerated dose (data not shown). Conversely, the alpha-
amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)
receptor antagonist, NBQX, inhibited the progression of
NSV-infected animals to moderate or severe levels of
paralysis (Fig. 1a), and prevented the destruction of motor




Fig. 2 Spinal cord expression of the main astroglial glutamate trans-
porter, GLT-1, declines over the course of acute NSV encephalomy-
elitis. (a) Immunohistochemical staining (brown) shows focal loss of
GLT-1 signal in the ventral gray matter of the lumbar spinal cord be-
tween early (day 2) and peak (day 6) infection. Expression returns to
baseline after acute infection has subsided (day 28), despite continued
paralysis in the few surviving animals at this late stage of disease (not
shown). GFAP expression is not significantly altered in adjacent tissue
sections, indicating the continued presence of astrocytes in spinal gray
matter throughout infection. (b) A representative western blot shows
that total lumbar spinal cord GLT-1 levels decline over the acute
stages of NSV infection while actin expression is preserved. (c)
Quantification (mean ± SEM) of GLT-1 and GFAP levels in lumbar
spinal cord normalized to actin and then to levels found in uninfected
control tissue shows the percent change of each protein over the
course of acute stages of disease (p < 0.05 indicating significantly
reduced levels compared to those detected in uninfected control ani-
mals as determined by Friedman’s non-parametric test).
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disease (Fig. 1b). Drug treatment also significantly enhanced
overall disease survival (Fig. 1 legend), although such a
difference is not likely the direct result of any effect on
lumbar spinal motor neurons that are the focus of the present
study. Our findings confirm the importance of glutamate
excitotoxicity in the spinal cord during alphavirus enceph-
alomyelitis and they justify further investigation into the
mechanisms that underlie activation of this cell death
pathway at this tissue site.
Selective loss of GLT-1 in the lumbar spinal cord
Removal of extracellular glutamate is largely dependent on
cellular reuptake by EAATs, and GLT-1, a protein expressed
primarily on astrocytes, is the dominant EAAT found in the
spinal cord (Rothstein et al. 1996; Anderson and Swanson
2000). To determine whether disrupted glutamate homeosta-
sis in the spinal cords of NSV-infected mice might be the
result of impaired transmitter reuptake, GLT-1 expression
was localized by immunohistochemical staining and quan-
tified by western blot. Analysis of lumbar spinal cord tissue
sections showed a focal loss of GLT-1 immunoreactivity
directly within the ventral gray matter where motor neuron
cell bodies reside (Fig. 2a). There was no associated loss of
GFAP staining to suggest a significant dropout of astrocytes
in these same regions, and tissue expression of GLT-1
recovered at late stages of disease even when there was no
return of hind limb motor function in the few surviving
animals (Fig. 2a, paralysis data not shown). Quantification of
spinal cord GLT-1 and GFAP expression by western blotting
showed that transporter levels began to decline immediately
prior to the onset of paralysis and progressed over the course
of the acute disease while GFAP levels remained stable
(Fig. 2c). Similar analyses also showed that spinal cord GLT-
1 levels declined in NBQX-treated animals, demonstrating
that transporter dysregulation precedes lumbar motor neuron
excitotoxicity (data not shown). Taken together, these data
suggest that an acquired and reversible defect in glutamate
reuptake by astrocytes locally within the lumbar spinal cord
may be responsible for the excitotoxic damage of adjacent
motor neuron cell bodies, thus causing the hind limb
paralysis that develops following NSV infection. Although
dropout of some astrocytes cannot be excluded, it seems
unlikely that a focal loss of these cells in spinal grey matter
can account for the observed effect on transporter
expression since GFAP levels were preserved throughout
disease and because GLT-1 immunoreactivity did eventually
recover.
Relationship between inflammatory cytokines and GLT-1
expression in the spinal cord
Further inspection of our immunostained spinal cord tissue
sections showed that loss of GLT-1 expression was most
pronounced in areas of robust tissue inflammation (Fig. 2a)
and microglial activation (data not shown). Since the
inflammatory cytokines, IL-1b and TNF-a, have both been
shown to suppress EAAT expression and glutamate reuptake
by astrocytes in vitro (Ye and Sontheimer 1996; Szymocha
et al. 2000; Wang et al. 2003; Korn et al. 2005), the
relationship between local tissue cytokine production, paral-
ysis, motor neuron degeneration, and GLT-1 expression was
investigated in the spinal cords of NSV-infected animals.
Analysis of tissue homogenates showed a rapid induction of
both IL-1b and TNF-a in the spinal cord following infection
(Fig. 3a and b), and treatment of animals with two unrelated
drugs, minocycline and naloxone, was effective at blunting
the IL-1b response in particular (Fig. 3a). Both drugs also
mitigated the severity of NSV-induced paralysis (Fig. 3c),
the degeneration of spinal motor neurons (Fig. 3d), and the
loss of spinal cord GLT-1 expression that ensued following
infection (Fig. 3e). These findings highlight a proposed
relationship between innate immune responses elicited in the
spinal cord by NSV infection and the loss of local GLT-1
expression leading to excitotoxic motor neuron injury.
Cytokine and GLT-1 levels in the spinal cords
of paralysis-resistant animals
The BALB/cBy substrain of BALB/c mice has previously
been shown to be resistant to NSV-induced paralysis through
Fig. 3 Levels of the pro-inflammatory cytokines, IL-1b and TNF-a,
increase in the spinal cord in parallel to GLT-1 loss and just prior to the
development of paralysis, while drugs that block induction of IL-1b also
limit paralysis, protect motor neurons, and mitigate the decline in GLT-
1 expression at this site. (a and b) Spinal cord levels of IL-1b and TNF-
a increase during acute NSV infection, and treatment of animals with
either minocycline (25 mg/kg twice daily) or naloxone (50 mg/kg/day)
blunts the IL-1b response. Mean ± SEM of cytokine levels in lumbar
spinal cord tissue homogenates at each time point are shown
(*p < 0.05 indicates significant reduction compared to untreated con-
trol animals at each time point as determined by the Kruskal–Wallis
test). (c) Both drug treatment regimens reduce the development and
severity of NSV-induced hind limb paralysis (significance determined
by Kaplan–Meier analysis), (d) and both prevent spinal motor neuron
degeneration compared to untreated controls (control data generated
separately and are the same as presented in Fig. 1b). Mortality was
100% in the control group shown in (c). Mean ± SEM of motor neuron
counts in lumbar spinal cord tissue sections are shown (*p < 0.05
indicates significantly improved cell survival compared to untreated
controls at each time point as determined by the Kruskal–Wallis test;
control data are the same as presented in Fig. 1b). (e) Both drugs also
prevent the decline in spinal cord GLT-1 levels during NSV infection as
measured by western blot. Mean ± SEM of the percent GLT-1
expression normalized to actin and then to levels found in uninfected
control spinal cords are shown (*p < 0.05 indicates significantly higher
levels compared to untreated control animals at each time point as
determined by the Kruskal–Wallis test; control data generated sepa-
rately and are the same as presented in Fig. 2c).
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a mechanism not related to either altered virus tropism or
impaired virus replication in the spinal cord (Thach et al.
2000). When spinal cord tissues from this host strain were
directly compared to samples obtained from highly suscep-
tible C57BL/6 mice, significantly higher baseline levels of
GLT-1 expression were observed (Fig. 4a). When both hosts
were challenged with NSV, not only were spinal motor
neurons more likely to survive in the resistant hosts (Fig. 4b),
but also there was significantly less IL-1b induced in the
spinal cord (Fig. 4c) and the expected decline of spinal cord
GLT-1 levels was blunted compared to the susceptible
animals (Fig. 4a). These data further enhance the proposed
link between local IL-1b induction and loss of GLT-1
expression in the spinal cord during acute NSV encephalo-
myelitis. They also highlight an interesting host strain
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transporter in the spinal cord that may also contribute to
paralysis resistance.
Paralysis and spinal cord GLT-1 levels in IL-1b-deficient
animals
Hind limb paralysis is attenuated in IL-1b-deficient
(IL-1b)/)) mice following NSV infection, although the
mechanisms underlying this altered disease phenotype
remain poorly understood (Liang et al. 1999). Because of
accumulating evidence linking IL-1b production in the spinal
cord with loss of GLT-1 expression during NSV infection,
experiments to more directly examine the relationship
between these two events were undertaken in IL-1b)/) mice.
Not only did we confirm that hind limb paralysis and spinal
motor neuron degeneration is attenuated in NSV-infected
IL-1b)/) mice compared to IL-1b+/+ controls (Fig. 5a
and b), but also that loss of spinal cord GLT-1 expression
during infection is highly dependent on the host’s capacity to
make IL-1b (Fig. 5c). Because infection clearly induces
significant IL-1b production in the spinal cord (Fig. 3a),
these data demonstrate that local actions of this inflammatory
cytokine are responsible for suppressing expression of this
glutamate transporter.
Discussion
Increasing evidence supports a link between innate immune
responses within the CNS and the development of excito-
toxic neuronal injury. Not only may endogenous immune
cells such as microglia be direct sources of glutamate (Noda
et al. 1999; Takeuchi et al. 2006; Barger et al. 2007), but
their various inflammatory products may also alter synaptic
glutamate homeostasis in a number of important ways. One
such mechanism is by inhibiting extracellular glutamate
reuptake, a process normally mediated by the EAATs
expressed on a variety of neural cell types. Astrocytes are
a major contributor to CNS glutamate reuptake, and by some
estimates, GLT-1 controls more than 90% of transmitter
clearance (Rothstein et al. 1996; Tanaka et al. 1997; Ander-




Fig. 4 Comparison of GLT-1 expression, motor neuron survival, and
IL-1b levels in the spinal cords of C57BL/6 (paralysis-susceptible) and
BALB/cBy (paralysis-resistant) mice following NSV infection. (a)
Spinal cord GLT-1 levels normalized to actin are significantly higher at
baseline in BALB/cBy mice than C57BL/6 animals (*p < 0.05 via the
Kruskal–Wallis test). While spinal cord GLT-1 expression declines in
both host strains over the course of acute NSV infection, the relative
drop is greater in C57BL/6 mice (p < 0.05 indicating significant
reduction compared to levels in uninfected control animals as deter-
mined via Friedman’s non-parametric test). (b) Spinal motor neurons
survive to a much greater degree in BALB/cBy mice following NSV
challenge. Mean ± SEM of motor neuron counts in lumbar spinal cord
tissue sections are shown (*p < 0.05 favoring the BALB/cBy mice
compared to the C57BL/6 animals at each time point as determined by
the Kruskal–Wallis test; data for the C57BL/6 mice generated sepa-
rately and is the same as presented in Figs 1b and 3d). (c) Induction of
IL-1b in spinal cord tissue during NSV infection is blunted in BALB/cBy
mice. Mean ± SEM of IL-1b levels in lumbar spinal cord tissue ho-
mogenates at each time point are shown (*p < 0.05 indicates signifi-
cant reduction compared to C57BL/6 control animals at each time
point as determined by the Kruskal–Wallis test; C57BL/6 data gener-
ated separately and is the same as presented in Fig. 3a).
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mediators on EAAT expression and glutamate reuptake by
astrocytes have been studied in vitro (Ye and Sontheimer
1996; Szymocha et al. 2000; Miralles et al. 2001; Wang
et al. 2003; Korn et al. 2005), although direct proof that such
mediators contribute to defects in glutamate reuptake and the
development of excitotoxicity in vivo is scarce. Here, we
show that production of the inflammatory cytokine, IL-1b,
suppresses GLT-1 expression in the spinal cord that, in turn,
drives the excitotoxic destruction of spinal motor neurons in
an experimental model of alphavirus encephalomyelitis. We
propose this finding has potential implications for under-
standing the pathogenesis of related CNS infectious and
inflammatory disorders as well.
Glutamate excitotoxicity has been known for some time to
underlie neuronal damage during CNS viral infection (Espey
et al. 1998). Its role is perhaps best studied in the NSV
model (Nargi-Aizenman and Griffin 2001; Darman et al.
2004; Nargi-Aizenman et al. 2004), even though the molec-
ular mechanisms that trigger this form of injury have until
recently remained poorly understood. Expanding evidence
suggests that host responses contribute to paralysis and death
during NSV infection (Liang et al. 1999; Irani and Prow
2007; Prow and Irani 2007), and we have used both
pharmacological and genetic strategies in the present study
to implicate the inflammatory cytokine, IL-1b, in mediating
excitotoxic spinal motor neuron injury via an induced defect
in glutamate reuptake. While some controversy surrounds the
mechanisms of action of both minocycline and naloxone as
neuroprotectants, emerging evidence suggests that both drugs
can target activated microglial cells to achieve this effect
(Yong et al. 2004; Qin et al. 2005). Interestingly, naloxone
may exert such an effect independent of its actions on classic
opioid receptors (Liu and Hong 2003; Qin et al. 2005). As to
our genetic approach, some caution must be used in
interpreting our results in the IL-1b)/) mice since non-
littermate, but otherwise age- and strain-matched, control
animals were used. Still, blockade of IL-1 receptors via an
exogenous IL-1 receptor antagonist attenuates NSV-induced




Fig. 5 Production of IL-1b in the spinal cord drives the development of
hind limb paralysis, motor neuron degeneration, and reduced local
GLT-1 expression during NSV encephalomyelitis. (a) Paralysis is less
severe in a cohort of IL-1b)/) mice compared to matched IL-1b+/+
controls following virus challenge. IL-1b deficiency also reduces dis-
ease mortality (15% in the IL-1b)/) mice, 80% in the IL-1b+/+ con-
trols, p = 0.0006), demonstrating that paralysis differences are not just
due to a shift between mild and moderate severity scores. The sig-
nificance of differences in paralysis and survival between the two
groups was determined by Kaplan–Meier analysis. (b) Motor neuron
survival is enhanced over the course of acute infection in the absence
of IL-1b. Mean ± SEM of motor neuron counts in lumbar spinal cord
tissue sections are shown (*p < 0.05 favoring the IL-1b)/) mice
compared to IL-1b+/+ controls at each time point as determined by the
Kruskal–Wallis test). (c) Finally, IL-1b deficiency prevents the decline
in spinal cord GLT-1 levels during NSV infection as measured by
western blot. Mean ± SEM of the percent GLT-1 expression normal-
ized to actin and then to levels found in uninfected control spinal cords
are shown (*p < 0.05 indicating significantly higher levels in the
IL-1b)/) mice compared to IL-1b+/+ controls at each time point as
determined by the Kruskal–Wallis test).
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mitigates the loss of spinal cord GLT-1 expression (data not
shown). Taken together, these findings implicate both IL-1b
production and IL-1 receptor signaling as being proximal
events in the glutamate transporter effects observed in this
model.
Impaired glutamate reuptake because of selective loss of
the astroglial glutamate transporter, GLT-1/EAAT2, is likely
to be a pathogenic event underlying the degeneration of
motor neurons in patients with ALS (Rothstein et al. 1992,
1995). Similar glutamate transport defects have also been
observed in the spinal cords of transgenic animals carrying a
mutant form of superoxide dismutase 1 (SOD1/G37R) that
models familial ALS (Howland et al. 2002; Warita et al.
2002; Dunlop et al. 2003). Recent studies conducted in these
transgenic animals suggest that innate immune responses,
many likely arising from activated microglial cells, accelerate
the degeneration of spinal motor neurons and the develop-
ment of overt weakness. Thus, treatment of transgenic
SOD1/G37R animals with drugs that inhibit microglial
activation delays both the onset and the progression of
disease (Zhu et al. 2002). Likewise, animals that carry a
mutant SOD1/G37R transgene that can be selectively deleted
in microglia have unaffected disease onset but show
significantly slower disease progression compared to non-
deleted controls (Boillée et al. 2006). Still, the precise
mechanisms through which microglia damage motor neurons
in these animals are poorly understood, and the molecular
connections between microglia and the pathways leading to
excitotoxic motor neuron injury remain undefined.
Among CNS viral infections, alphaviruses and the related
flaviviruses are important causes of fatal encephalomyelitis
in humans worldwide. Most are transmitted in nature via
infected mosquito vectors. While neurological disease caused
by these viruses occurs with a wide array of clinical features,
prominent spinal cord infection with paralysis and motor
neuron destruction is one common phenotype (Solomon
et al. 1998; Davis et al. 2006). Unfortunately, antiviral
agents with activity against the alphaviruses and flaviviruses
are not available, and consequently, management of patients
with these infections remains supportive. In lieu of therapies
directed against the pathogen itself, however, we have
recently proposed that interventions can be targeted against
detrimental host responses to exert neuroprotective effects
(Nargi-Aizenman et al. 2004; Irani and Prow 2007; Prow
and Irani 2007). If impaired glutamate transporter expression
and/or function resulting from local tissue inflammation
proves to occur in humans with these infections, then this
cascade of events becomes even more important to under-
stand and exploit as a novel treatment approach.
Beyond viral encephalomyelitis, glutamate-mediated
excitotoxicity has now also been implicated in the patho-
genesis of CNS inflammatory demyelinating diseases of both
animals and humans (Pitt et al. 2000, 2003; Smith et al.
2000; Werner et al. 2001; Srinivasan et al. 2005). In mice,
blockade of AMPA receptors ameliorates clinical disease in
the experimental autoimmune encephalomyelitis (EAE)
model without altering the amount of CNS inflammation or
the extent of myelin loss (Pitt et al. 2000). Subsequent
studies in EAE have shown that GLT-1 expression is
profoundly reduced within demyelinated lesions, and that
protein levels do not recover even after clinical remission
(Ohgoh et al. 2002). Furthermore, this reduced expression is
prevented in animals treated with NBQX, suggesting that
AMPA receptor activation precedes the altered expression of
glutamate transporters (Ohgoh et al. 2002). In humans with
multiple sclerosis (MS), careful immunopathological study
of cortical demyelination reveals that expression of EAAT1
and EAAT2 are selectively reduced in lesions where
activated microglia are found (Vercellino et al. 2007).
Soluble inflammatory mediators have been proposed to
underlie these changes in transporter expression (Werner
et al. 2001; Vercellino et al. 2007), but the specific molec-
ular mechanisms are not known. Our data suggest that
proinflammatory cytokines such as IL-1b could be respon-
sible for these effects, and by extension, that inhibiting their
production or action could offer a novel neuroprotective
strategy for use in MS patients. Certainly, there are already
approved compounds known to offer neuroprotection by
increasing baseline astrocyte glutamate transporter expres-
sion (Rothstein et al. 2005).
Control of astroglial glutamate transporters can occur at a
transcriptional, translational, or post-translational level. Spe-
cific transcription factors have been shown to directly repress
the GLT-1/EAAT2 gene (Sitcheran et al. 2005; Li et al.
2006), and a common polymorphism in the EAAT2 promoter
has recently been identified in humans that influences
transcription factor binding and the susceptibility to excito-
toxic injury following stroke (Mallolas et al. 2006). At post-
transcriptional stages, some EAAT2 mRNAs contain lengthy
5¢-untranslated regions that influence their translation (Tian
et al. 2007). Even once a functional protein is expressed on
the astrocyte cell surface, some cellular signals cause rapid
transporter internalization (Kalandadze et al. 2002; González
et al. 2005), while others inhibit transporter function without
changing cell surface levels (Volterra et al. 1994; Trotti et al.
1996). Extracellular cytokines are known to inhibit GLT-1
transcription (Sitcheran et al. 2005), but we do not yet know
to what degree our observed effects of IL-1b on GLT-1
function in vivo occur at a transcriptional level.
In conclusion, our data show that local production of IL-
1b in the spinal cords of NSV-infected mice causes
clinically-significant loss of the main astroglial glutamate
transporter, GLT-1, and leads to excitotoxic damage of spinal
motor neurons. Drugs that inhibit IL-1b production and/or
action on IL-1 receptors protect against these cellular events
and limit the development of paralysis. We believe these
findings have important clinical implications for understand-
ing the neurodegeneration that occurs with other CNS
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inflammatory diseases, as they offer a molecular pathway
that is amenable to therapeutic manipulation.
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